Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

A new resource at Vanderbilt is helping medical students, residents and even long-standing medical faculty to enhance their palliative care skills.

A new combination treatment showed promise in slowing the growth of castration-resistant prostate cancer in animal models, Vanderbilt researchers discovered.

C.J. Stimson, MD, JD, assistant professor of Urology at Vanderbilt University Medical Center, has been named Chief Medical Officer (CMO) of the VUMC and Vanderbilt University Employee Health Plans.

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

H. Rodes Hart, BA’54, and Patricia Ingram Hart, BA’57, whose generous gifts continue to advance the mission of Vanderbilt as one of the world’s great universities for learning and discovery, have endowed a second chair in Urologic Surgery.

A neurostimulator surgically implanted above the buttocks to reprogram how the bladder senses the filling of urine is helping patients with debilitating bladder and bowel disorders that are often life-limiting.